The 5 most recent market catalysts affecting $TGTX, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 1, 2026
Corporate Catalyst
Neutral
Impact 55
HC Wainwright & Co. Reiterates Buy on TG Therapeutics, Maintains $78 Price Target
HC Wainwright & Co. analyst Emily Bodnar has reiterated a 'Buy' rating for TG Therapeutics (TGTX) and maintained a $78 price target. This event indicates that the analyst firm cont…
Aug 21, 2026
Corporate Catalyst
Neutral
Impact 85
Watching TG Therapeutics; Traders Speculate Multiple Parties Interested To Acquire TG Therapeutics
This headline represents a significant corporate catalyst for TG Therapeutics. Acquisition speculation, especially involving 'multiple parties,' often leads to a substantial increa…
Aug 7, 2026
Corporate Catalyst
Bullish
Impact 55
JP Morgan Maintains Overweight on TG Therapeutics, Raises Price Target to $72
JP Morgan analyst Brian Cheng has maintained an 'Overweight' rating on TG Therapeutics and raised the price target from $65 to $72. This action signals a positive outlook from a ma…
Aug 3, 2026
Corporate Catalyst
Bearish
Impact 75
TG Therapeutics shares are trading lower after the company reported worse-than-expected Q2 EPS results.
This headline directly impacts TG Therapeutics (TGTX) as it signals a failure to meet analyst expectations for earnings per share. Such a miss often leads to immediate stock price …
Aug 3, 2026
Corporate Catalyst
Bearish
Impact 92
TG Therapeutics Q2 EPS $0.05 Misses $0.33 Estimate, Sales $240.335M Beat $229.721M Estimate
TG Therapeutics' Q2 earnings report presents a mixed picture. The significant miss on EPS (84.85% below consensus) is a major concern for investors, suggesting potential issues wit…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.